Search Result

Results for "

TLR antagonist

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Toll-like Receptor (TLR) (48) AIM2 (2) Apoptosis (1) Bacterial (1) EBV (1) HIV (1) HSP (1) Interleukin Related (10) MyD88 (1) NF-κB (11) NO Synthase (3) Opioid Receptor (2) p38 MAPK (3) Pyroptosis (1) STAT (2) Stearoyl-CoA Desaturase (SCD) (3) TNF Receptor (4)
By Research Areas:	Cancer (7) Cardiovascular Disease (2) Infection (5) Inflammation/Immunology (44) Metabolic Disease (3) Neurological Disease (7)
Oligonucleotides:	CpG ODNs (8)

Inhibitors & Agonists

Peptides

Natural
Products

Oligonucleotides

Targets Recommended: Toll-like Receptor (TLR)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-150751

ODN TTAGGG 3 Publications Verification ODN A151	Toll-like Receptor (TLR) AIM2 Pyroptosis Interleukin Related	Inflammation/Immunology
ODN TTAGGG (ODN A151), an inhibitory oligonucleotide (ODN), is a *TLR9, AIM2, and cGAS* antagonist. ODN TTAGGG inhibits AIM2 inflammasome activation and cGAS activation through competition with DNA. ODN TTAGGG blocks AIM2-mediated Pyroptosis and inhibits IL-18 production. ODN TTAGGG has immunosuppressive effects and can be used in research on related autoimmune diseases such as lupus erythematosus . ODN TTAGGG sequence: 5'-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-3'.

HY-139567

Afimetoran 1 Publications Verification BMS-986256	Toll-like Receptor (TLR) NF-κB Apoptosis	Inflammation/Immunology
Afimetoran (BMS-986256) is an orally active, selective, and highly bioavailable *TLR7/8* antagonist. Afimetoran (BMS-986256) can inhibit *TLR7/8* activation of the NF-κB pathway and reverse *TLR7* mediated resistance to steroid induced apoptosis in plasma cell like dendritic cells (pDCs). Afimetoran (BMS-986256) can be used for research on inflammation and autoimmune diseases (systemic lupus erythematosus) .

HY-112146

MMG-11 5 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology
MMG-11 is a potent and selective human *TLR2* antagonist with low cytotoxicity. MMG-11 inhibits both TLR2/1 and TLR2/6 signaling with IC₅₀s of 1.7 µM for Pam₃CSK₄-induced hTLR2/1 and 5.7 µM for Pam₂CSK₄-induced hTLR2/6 responses .

HY-12756A

E6446 dihydrochloride 5+ Cited Publications	Toll-like Receptor (TLR) Stearoyl-CoA Desaturase (SCD)	Metabolic Disease Inflammation/Immunology
E6446 dihydrochloride is a potent and orally acitve *TLR7* and *TLR9* antagonist, used in the research of deleterious inflammatory responses. E6446 dihydrochloride is also a potent SCD1 inhibitor (KD: 4.61 μM), significantly inhibiting adipogenic differentiation and hepatic lipogenesis through SCD1-ATF3 signaling. E6446 dihydrochloride also improves liver pathology in high-fat diet (HFD)-fed mice and may be useful in the study of non-alcoholic fatty liver disease (NAFLD) .

HY-116213

Sparstolonin B 5+ Cited Publications	Toll-like Receptor (TLR) HIV	Infection Inflammation/Immunology Cancer
Sparstolonin B acts as a selective *TLR2* and *TLR4* antagonist and selectively blocks TLR2- and TLR4-mediated inflammatory signaling. Sparstolonin B has anti-HIV and anticancer activities .

HY-116961

TH1020 Maximum Cited Publications 13 Publications Verification	Toll-like Receptor (TLR) Bacterial	Infection Inflammation/Immunology
TH1020 is a potent and selective *toll-like receptor 5 (TLR5)/flagellin complex* antagonist with an IC₅₀ of 0.85 μM. TH1020 inhbits flagellin-induced *TLR5* signaling. TH1020 is inactive against TLR2, TLR3, TLR4, TLR7 and TLR8 .

HY-125171

IAXO-102 5 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology
IAXO-102 is a *TLR4* antagonist which negatively regulates TLR4 signalling. IAXO-102 inhibits MAPK and p65 NF-κB phosphorylation and expression of TLR4 dependent proinflammatory protein. IAXO-102 also prevents experimental abdominal aortic aneurysm development .

HY-128598

MD2-TLR4-IN-1 1 Publications Verification	Toll-like Receptor (TLR) NF-κB	Inflammation/Immunology Cancer
MD2-TLR4-IN-1 is a myeloid differentiation protein 2/toll-like receptor 4 (MD2-TLR4) complex antagonist. MD2-TLR4-IN-1 inhibits Lipopolysaccharides (HY-D1056) (LPS)-induced expression of TNF-α and IL-6 in macrophages with IC₅₀ values of 0.89 μM and 0.53 μM, respectively. MD2-TLR4-IN-1 can be used for the study of acute lung injury (ALI) .

HY-12756

E6446 5+ Cited Publications	Toll-like Receptor (TLR) Stearoyl-CoA Desaturase (SCD)	Metabolic Disease Inflammation/Immunology
E6446 is a potent and orally acitve *TLR7* and *TLR9* antagonist, used in the research of deleterious inflammatory responses. E6446 is also a potent SCD1 inhibitor (KD: 4.61 μM), significantly inhibiting adipogenic differentiation and hepatic lipogenesis through SCD1-ATF3 signaling. E6446 also improves liver pathology in high-fat diet (HFD)-fed mice and may be useful in the study of non-alcoholic fatty liver disease (NAFLD) .

HY-112050

CU-CPT-8m 2 Publications Verification TLR8-specific antagonist	Toll-like Receptor (TLR)	Inflammation/Immunology
CU-CPT-8m is a specific *TLR8* antagonist, with an IC₅₀ of 67 nM.

HY-150751C

ODN TTAGGG sodium 3 Publications Verification ODN A151 sodium	AIM2 Toll-like Receptor (TLR)	Inflammation/Immunology
ODN TTAGGG sodium, inhibitory oligonucleotide (ODN), is a *TLR9, AIM2* and cGAS antagonist. ODN TTAGGG sodium is immunosuppressive and inhibits AIM2 inflammasome activation, as well as cGAS activation, by competing with DNA. ODN TTAGGG sodium can be used in the study of lupus erythematosus and other related autoimmune diseases. ODN TTAGGG sequence: 5'-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-3' .

HY-112667

CU-CPT-9a 5 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology
CU-CPT-9a is a specific *TLR8* antagonist, with an IC₅₀ of 0.5 nM.

HY-112051

CU-CPT9b 1 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology
CU-CPT9b is a specific *TLR8* antagonist, with an IC₅₀ of 0.7 nM. CU-CPT9b shows high binding affinity towards TLR8 with a K_d of 21 nM .

HY-135042

CAY10614 1 Publications Verification	Toll-like Receptor (TLR)	Neurological Disease
CAY10614 is a potent *TLR4* antagonist. CAY10614 inhibits the lipid A-induced activation of TLR4, with an IC₅₀ of 1.675 μM. CAY10614 can improve survival of mice in lethal endotoxin shock model .

HY-153460

TLR7/8/9 antagonist 2	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7/8/9 antagonist 2 is an orally active *TLR7/8/9* antagonist. TLR7/8/9 antagonist 2 has inhibitory activities for HEK/hTLR7, HEK/hTLR8 and HEK/hTLR9 with IC₅₀ values of 0.011 μM, 0.029 μM and 0,052 μM, respectively.TLR7/8/9 antagonist 2 has high bioavailability in vivo.TLR7/8/9 antagonist 2 can be used for the research of auto-inflammatory diseases such as systemic lupus erythematosus or lupus nephritis .

HY-105070A

Eritoran tetrasodium E5564	EBV Toll-like Receptor (TLR)	Infection Inflammation/Immunology
Eritoran tetrasodium (E5564) is a Toll-like receptor 4 (TLR4) antagonist. Eritoran tetrasodium protects mice against lethal influenza virus infection, such as Ebola virus (EBOV), Marburg virus (MARV). Eritoran tetrasodium decreases the level of granulocytosis, may alleviate the severity of the "cytokine storm". Eritoran tetrasodium inhibits pathogenesis of filovirus infection. Eritoran tetrasodium has anti-inflammatory activity .

HY-131945

CU-115 2 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology
CU-115 is a potent TLR8 antagonist (IC₅₀=1.04 µM), and shows selective for TLR8 over TLR7 (IC₅₀=>50 µM). CU-115 decreases TNF-α and IL-1β production activated by R-848 in THP-1 cells .

HY-144619

TLR7/8 antagonist 2	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7/8 antagonist 2 (Compound 15) is a potent and orally active agonist of *TLR7/8* with IC₅₀s of 4.9 and 0.6 nM, respectively. Inappropriate activation of TLR7 and TLR8 is linked to several autoimmune diseases, such as lupus erythematosus. TLR7/8 antagonist 2 has the potential for the research of autoimmune diseases .

HY-18325

AN-3485 1 Publications Verification	Toll-like Receptor (TLR) NF-κB Interleukin Related	Inflammation/Immunology Cancer
AN-3485 is a benzoxaborole analogue and an orally active antagonist of the Toll-like pathway. AN-3485 can inhibit *TLR*-mediated inflammatory cytokine secretion and has significant anti-inflammatory activity. In addition, AN-3485 also has certain anti-tumor activity .

HY-131952

TLR7/8/9-IN-1 2 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology
TLR7/8/9-IN-1 is a potent and orally bioavailable small molecule antagonist (IC₅₀ = 43 nM) of Toll-like receptors 7/8/9 (TLR7/8/9).

HY-175533

TLR2 antagonist-1	Toll-like Receptor (TLR)	Neurological Disease Inflammation/Immunology
TLR2 antagonist-1 is a selective Toll-like receptor 2 (TLR2) antagonist. TLR2 antagonist-1 can effectively inhibit excessive TLR2 activation (IC₅₀ = 11.41 μM) and the production of inflammatory factors. TLR2 antagonist-1 has metabolic stability with a half-life (T_1/2) of 16.67 min in mouse liver microsomes. TLR2 antagonist-1 can be used for the researches of inflammation, immunology, and neurological disease .

HY-178037

TLR9 antagonist 1	Toll-like Receptor (TLR) Interleukin Related TNF Receptor	Inflammation/Immunology
TLR9 antagonist 1 is a selective hTLR9 antagonist with an IC₅₀ of 0.1 nM against hTLR9. TLR9 antagonist 1 exhibits favorable pharmacokinetic and pharmacodynamic properties. TLR9 antagonist 1 can be used in the research of systemic lupus erythematosus .

HY-145886

TLR7/8 antagonist 1	Toll-like Receptor (TLR) Interleukin Related	Infection Inflammation/Immunology Cancer
TLR7/8 antagonist 1 (Compound 16c) is a competitive *TLR7/8* antagonist with IC₅₀ values of 3.91 μM and 2.19 μM, respectively. TLR7/8 antagonist 1 reduces agonist-induced production of proinflammatory cytokines, including TNFα, IFNγ and IL-1β .

HY-120538

CPG-52364	Toll-like Receptor (TLR)	Inflammation/Immunology
CPG-52364 (compound 2) is a TLR9 antagonist. CPG-52364 inhibits the HEK293-hTLR9 cell with an IC₅₀ value of 4.6 nM .

HY-101318

β-Funaltrexamine hydrochloride 2 Publications Verification β-FNA hydrochloride	Opioid Receptor p38 MAPK STAT NF-κB NO Synthase Toll-like Receptor (TLR)	Cardiovascular Disease Neurological Disease
β-Funaltrexamine (β-FNA) hydrochloride is a blood-brain barrier-permeable, selective and irreversible μ-opioid receptor antagonist with immunomodulatory, anti-inflammatory and neuroprotective activities. β-Funaltrexamine hydrochloride inhibits p38 MAPK and *TLR4* signaling by blocking μ-opioid receptors, and reduces the transcriptional activities of NF-κB, AP-1, CREB and Stat. Furthermore, β-Funaltrexamine hydrochloride inhibits iNOS activation and pro-inflammatory microglial polarization, converting microglia to an anti-inflammatory phenotype, thereby downregulating neuroinflammation and ameliorating neuronal degeneration. β-Funaltrexamine hydrochloride is widely applicable to research related to stroke, cerebral ischemia/reperfusion injury and neurodegenerative diseases .

HY-173063

TLR8 antagonist-1	Toll-like Receptor (TLR) NF-κB MyD88	Inflammation/Immunology
TLR8 antagonist-1 (Compound 10) is a selective *TLR8* antagonist. TLR8 antagonist-1 can inhibit TLR8-mediated inflammation and signaling pathways, reduce the recruitment of MyD88, and inhibit the NF-κB and IRF pathways. TLR8 antagonist-1 has anti-inflammatory activity .

HY-112146A

MMG-11 quarterhydrate 5 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology
MMG-11 quarterhydrate is a potent and selective human *TLR2* antagonist with low cytotoxicity. MMG-11 quarterhydrate inhibits both TLR2/1 and TLR2/6 signaling with IC₅₀s of 1.7 μM for Pam₃CSK₄-induced hTLR2/1 and 5.7 μM for Pam₂CSK₄-induced hTLR2/6 responses .

HY-177617

Bazlitoran IMO-8400	Toll-like Receptor (TLR)	Inflammation/Immunology
Bazlitoran (IMO-8400) is an oligonucleotide-based *TLR7/8/9* antagonist. Bazlitoran blocks the activation of Toll-like receptors 7, 8, and 9. Bazlitoran inhibits cytokine responses mediated by Toll-like receptors 7, 8, and 9. Bazlitoran is associated with injection site reactions. Bazlitoran improves moderate-to-severe plaque psoriasis .

HY-178037A

TLR9 antagonist 1 diformate	Interleukin Related TNF Receptor Toll-like Receptor (TLR)	Inflammation/Immunology
TLR9 antagonist 1 diformate is a selective hTLR9 antagonist with an IC₅₀ of 0.1 nM against hTLR9. TLR9 antagonist 1 diformate exhibits favorable pharmacokinetic and pharmacodynamic properties. TLR9 antagonist 1 diformate can be used in the research of systemic lupus erythematosus .

HY-177617A

Bazlitoran sodium IMO-8400 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
Bazlitoran sodium (IMO-8400 sodium) is an oligonucleotide-based *TLR7/8/9* antagonist. Bazlitoran sodium blocks the activation of Toll-like receptors 7, 8, and 9. Bazlitoran sodium inhibits cytokine responses mediated by Toll-like receptors 7, 8, and 9. Bazlitoran sodium is associated with injection site reactions. Bazlitoran sodium improves moderate-to-severe plaque psoriasis .

HY-123789

T5342126 1 Publications Verification	Toll-like Receptor (TLR)	Inflammation/Immunology
T-5342126 is a toll-like receptor 4 (TLR4) antagonist. It reduces LPS-induced production of nitric oxide (NO) in RAW 264.7 cells (IC₅₀=27.8 μM), as well as decreases LPS-induced IL-8, TNF-α, and IL-6 production in isolated human whole blood (IC₅₀s=110.5, 315.6, and 318.4 μM, respectively). T-5342126 (82 mg/kg) reduces ethanol intake and the abundance of ionized calcium-binding adapter molecule 1 (Iba1), a marker of microglial activation, in the central nucleus of the amygdala in ethanol-dependent mice.

HY-177623

CpG-ODN c41 CpG-c41	Toll-like Receptor (TLR)	Inflammation/Immunology
CpG-ODN c41, an oligonucleotide, is an antagonist of TLR9.

HY-P11052

A8 peptide	HSP	Cancer
A8 peptide is a Hsp72 antagonist. A8 peptide inhibits tumor progression and metastasis as well as enhances the cancer cells' sensitivity to apoptosis induced by chemotherapeutic agents (such as Cisplatin (HY-17394)) by blocking the Hsp72-TLR2 interaction and the subsequent activation of MDSCs. A8 peptide can be used for cancers research .

HY-118984

CRX-526	Toll-like Receptor (TLR)	Inflammation/Immunology
CRX-526 is a *TLR4* antagonist that can block the interaction of lipopolysaccharide (LPS, HY-D1056) with the immune system, including preventing the expression of pro-inflammatory genes stimulated by LPS, as well as blocking the release of TNF-α induced by LPS. CRX-526 exhibits anti-inflammatory effects in two mouse models of colitis (namely, the dextran sodium sulfate-induced colitis model and the multidrug resistance gene 1a-deficient mouse model) .

HY-124709

TLR9 antagonist 2	Toll-like Receptor (TLR) Interleukin Related	Inflammation/Immunology
TLR9 antagonist 2 is a highly selective and water-soluble *TLR9* antagonist with an IC₅₀ of 13 nM against human TLR9. TLR9 antagonist 2 inhibits CpG-induced production of the pro-inflammatory cytokine IL-6. TLR9 antagonist 2 is applicable for research on systemic, TLR9-mediated uncontrolled inflammatory responses, such as sepsis .

HY-180507

TLR2/9 antagonist 1	Toll-like Receptor (TLR)	Neurological Disease Inflammation/Immunology Cancer
TLR2/9 antagonist 1 (Compound 24) is a reversible covalent *TLR2* (IC₅₀ = 0.5 μM (TLR2/TLR6); IC₅₀ = 0.6 μM (TLR2/TLR1)) and *TLR9* (IC₅₀ = 0.32 μM) antagonist. TLR2/9 antagonist 1 has no significant effect on other TLR subtypes. TLR2/9 antagonist 1 can be used for studying central nervous system diseases and malignant tumors caused by inflammation .

HY-183276

TLR8 antagonist-2	Toll-like Receptor (TLR) NF-κB	Inflammation/Immunology
TLR8 antagonist-2 (Compound 35) is a selective *TLR8* antagonist with an IC₅₀ of 0.032 μM against hTLR8. TLR8 antagonist-2 potently inhibits TLR8-dependent NF-κB activity in cells stimulated with TL8-506 (HY-20457). TLR8 antagonist-2 can be used in research related to inflammatory and immune diseases .

HY-181796

TLR7 antagonist-1	Toll-like Receptor (TLR) Interleukin Related	Inflammation/Immunology
TLR7 antagonist-1 (Compound 44#) is an orally active, selective *TLR7* antagonist with an IC₅₀ value of 0.3 nM against *TLR7. TLR7 antagonist-1 selectively binds to TLR7, inhibits its activation, and downregulates the c-Rel* signaling pathway. TLR7 antagonist-1 downregulates the mRNA levels of proinflammatory cytokines IL-1β, IL-6, and TNF-α. TLR7 antagonist-1 alleviates Imiquimod (HY-B0180)-induced psoriasis-like skin lesions. TLR7 antagonist-1 is applicable to research related to psoriasis .

HY-P10208

RKH	Toll-like Receptor (TLR)	Infection
PKH is a *TLR4* antagonist. PKH is a novel tripeptide and can be isolated from Akkermansia muciniphila. RKH reduces sepsis-induced inflammatory cell activation and proinflammatory factor overproduction .

HY-150751A

Biotin-labeled ODN TTAGGG sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
Biotin-labeled ODN TTAGGG (sodium), a inhibitory oligonucleotide (ODN), is a *TLR9, AIM2* and cGAS antagonist. Biotin-labeled ODN TTAGGG (sodium) can be used to evaluate CpG ODN cellular uptake and localization using a biotin detection system and light microscopy.

HY-150751B

FITC-labeled ODN TTAGGG sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
FITC-labeled ODN TTAGGG (sodium), a inhibitory oligonucleotide (ODN), is a *TLR9, AIM2* and cGAS antagonist. FITC-labeled ODN TTAGGG (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.

HY-18325A

AN-3485 hydrochloride	Toll-like Receptor (TLR) NF-κB Interleukin Related	Inflammation/Immunology Cancer
AN-3485 hydrochloride is a benzoxaborole analogue and an orally active antagonist of the Toll-like pathway. AN-3485 hydrochloride can inhibit *TLR*-mediated inflammatory cytokine secretion and has significant anti-inflammatory activity. In addition, AN-3485 hydrochloride also has certain anti-tumor activity .

HY-12756AR

E6446 dihydrochloride (Standard)	Toll-like Receptor (TLR) Stearoyl-CoA Desaturase (SCD)	Metabolic Disease Inflammation/Immunology
E6446 (dihydrochloride) (Standard) is the analytical standard of E6446 (dihydrochloride). This product is intended for research and analytical applications. E6446 dihydrochloride is a potent and orally acitve TLR7 and TLR9 antagonist, used in the research of deleterious inflammatory responses. E6446 dihydrochloride is also a potent SCD1 inhibitor (KD: 4.61 μM), significantly inhibiting adipogenic differentiation and hepatic lipogenesis through SCD1-ATF3 signaling. E6446 dihydrochloride also improves liver pathology in high-fat diet (HFD)-fed mice and may be useful in the study of non-alcoholic fatty liver disease (NAFLD) .

HY-175782

SMU-R39	Toll-like Receptor (TLR) NF-κB p38 MAPK	Inflammation/Immunology
SMU-R39 is a *TLR7* and TLR8 antagonist with IC₅₀ values of 3.22 μM and 0.24 μM, respectively. SMU-R39 binds to recombinant mTLR7 protein (K_D = 2.36 μM) and to recombinant hTLR8 protein (K_D = 105 nM). SMU-R39 suppresses downstream NF-κB and MAPK signaling, and reduces secretion/transcription of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in PBMCs and THP-1 cells. SMU-R39 demonstrates anti-inflammatory efficacy in Imiquimod (IMQ) (HY-B0180)-induced psoriasis mouse model. SMU-R39 can be used for the study of autoimmune diseases such as psoriasis .

HY-181884

TLR9-IN-3		Inflammation/Immunology
TLR9-IN-3 is a *TLR9* antagonist with an IC₅₀ of 0.4 μM. TLR9-IN-3 shows selectivity for TLR4 and TLR8, and inhibits CD69 activation in human whole blood with a corresponding IC₅₀ of 1.1 μM. TLR9-IN-3 can be used in research related to pulmonary fibrosis .

HY-177623A

CpG-ODN c41 sodium CpG-c41 sodium	Toll-like Receptor (TLR)	Inflammation/Immunology
CpG-ODN c41 sodium, an oligonucleotide, is an antagonist of TLR9.

HY-157961

E-5531	Toll-like Receptor (TLR)	Inflammation/Immunology
E-5531 is an endotoxin antagonist. E-5531 quickly becomes inactive after binding with HDL. E-5531 can block the Toll like receptor 4 *(TLR4)* signaling pathway. E-5531 can be used for the study of endotoxemia and septic shock .

HY-179646

CIAC101	Toll-like Receptor (TLR) NO Synthase NF-κB TNF Receptor Interleukin Related	Neurological Disease
CIAC101 is a potent and brain-penetrant *TLR4* antagonist with an IC₅₀ of 17.0 nM in NO assay. CIAC101 blocks Lipopolysaccharides (HY-D1056) (LPS)-induced NF-κB activation and reduces the expression of pro-inflammatory mediators (iNOS, IL-1β, TNF-α, and IL-6). CIAC101 robust antineuroinflammatory activity with efficacy against drug-evoked neurobehavioral adaptations. CIAC101 can be used for the research of addiction and neurological disease .

HY-160938

β-Funaltrexamine β-FNA	Opioid Receptor STAT NF-κB Toll-like Receptor (TLR) NO Synthase p38 MAPK	Cardiovascular Disease Neurological Disease
β-Funaltrexamine (β-FNA) is a blood-brain barrier-permeable, selective and irreversible μ-opioid receptor antagonist with immunomodulatory, anti-inflammatory and neuroprotective activities. β-Funaltrexamine inhibits p38 MAPK and *TLR4* signaling by blocking μ-opioid receptors, and reduces the transcriptional activities of NF-κB, AP-1, CREB and Stat. Furthermore, β-Funaltrexamine inhibits iNOS activation and pro-inflammatory microglial polarization, converting microglia to an anti-inflammatory phenotype, thereby downregulating neuroinflammation and ameliorating neuronal degeneration. β-Funaltrexamine is widely applicable to research related to stroke, cerebral ischemia/reperfusion injury and neurodegenerative diseases .

HY-N19801

N-Palmitoyl-D-glucosamine	Toll-like Receptor (TLR) NF-κB Interleukin Related TNF Receptor	Neurological Disease Inflammation/Immunology
N-Palmitoyl-D-glucosamine is an orally active *TLR4* antagonist. N-Palmitoyl-D-glucosamine stably binds MD-2 with, preventing LPS-induced NF-κB signaling, decreases pro-inflammatory cytokines (IL-1β, TNF-α, and IL-6), increases anti-inflammatory IL-10 and IL-1rα, and normalizes miR-20a-5p, miR-106a-5p, and miR-27a-3p levels. N-Palmitoyl-D-glucosamine decreases allodynia and prevents myelino-axonal degeneration of peripheral nerves. N-Palmitoyl-D-glucosamine can be used for the researches of keratitis and peripheral neuropathy .

Cat. No.	Product Name	Target	Research Area

HY-P11052

A8 peptide	HSP	Cancer
A8 peptide is a Hsp72 antagonist. A8 peptide inhibits tumor progression and metastasis as well as enhances the cancer cells' sensitivity to apoptosis induced by chemotherapeutic agents (such as Cisplatin (HY-17394)) by blocking the Hsp72-TLR2 interaction and the subsequent activation of MDSCs. A8 peptide can be used for cancers research .

HY-P10208

RKH	Toll-like Receptor (TLR)	Infection
PKH is a *TLR4* antagonist. PKH is a novel tripeptide and can be isolated from Akkermansia muciniphila. RKH reduces sepsis-induced inflammatory cell activation and proinflammatory factor overproduction .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N19801

N-Palmitoyl-D-glucosamine	Structural Classification Natural Products Microorganisms Source Classification	Toll-like Receptor (TLR) NF-κB Interleukin Related TNF Receptor
N-Palmitoyl-D-glucosamine is an orally active *TLR4* antagonist. N-Palmitoyl-D-glucosamine stably binds MD-2 with, preventing LPS-induced NF-κB signaling, decreases pro-inflammatory cytokines (IL-1β, TNF-α, and IL-6), increases anti-inflammatory IL-10 and IL-1rα, and normalizes miR-20a-5p, miR-106a-5p, and miR-27a-3p levels. N-Palmitoyl-D-glucosamine decreases allodynia and prevents myelino-axonal degeneration of peripheral nerves. N-Palmitoyl-D-glucosamine can be used for the researches of keratitis and peripheral neuropathy .

Cat. No.	Product Name		Classification

HY-150751

ODN TTAGGG 3 Publications Verification ODN A151		CpG ODNs
ODN TTAGGG (ODN A151), an inhibitory oligonucleotide (ODN), is a *TLR9, AIM2, and cGAS* antagonist. ODN TTAGGG inhibits AIM2 inflammasome activation and cGAS activation through competition with DNA. ODN TTAGGG blocks AIM2-mediated Pyroptosis and inhibits IL-18 production. ODN TTAGGG has immunosuppressive effects and can be used in research on related autoimmune diseases such as lupus erythematosus . ODN TTAGGG sequence: 5'-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-3'.

HY-150751C

ODN TTAGGG sodium 3 Publications Verification ODN A151 sodium		CpG ODNs
ODN TTAGGG sodium, inhibitory oligonucleotide (ODN), is a *TLR9, AIM2* and cGAS antagonist. ODN TTAGGG sodium is immunosuppressive and inhibits AIM2 inflammasome activation, as well as cGAS activation, by competing with DNA. ODN TTAGGG sodium can be used in the study of lupus erythematosus and other related autoimmune diseases. ODN TTAGGG sequence: 5'-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-T-T-A-G-G-G-3' .

HY-177617

Bazlitoran IMO-8400		CpG ODNs
Bazlitoran (IMO-8400) is an oligonucleotide-based *TLR7/8/9* antagonist. Bazlitoran blocks the activation of Toll-like receptors 7, 8, and 9. Bazlitoran inhibits cytokine responses mediated by Toll-like receptors 7, 8, and 9. Bazlitoran is associated with injection site reactions. Bazlitoran improves moderate-to-severe plaque psoriasis .

HY-177617A

Bazlitoran sodium IMO-8400 sodium		CpG ODNs
Bazlitoran sodium (IMO-8400 sodium) is an oligonucleotide-based *TLR7/8/9* antagonist. Bazlitoran sodium blocks the activation of Toll-like receptors 7, 8, and 9. Bazlitoran sodium inhibits cytokine responses mediated by Toll-like receptors 7, 8, and 9. Bazlitoran sodium is associated with injection site reactions. Bazlitoran sodium improves moderate-to-severe plaque psoriasis .

HY-177623

CpG-ODN c41 CpG-c41		CpG ODNs
CpG-ODN c41, an oligonucleotide, is an antagonist of TLR9.

HY-150751A

Biotin-labeled ODN TTAGGG sodium		CpG ODNs
Biotin-labeled ODN TTAGGG (sodium), a inhibitory oligonucleotide (ODN), is a *TLR9, AIM2* and cGAS antagonist. Biotin-labeled ODN TTAGGG (sodium) can be used to evaluate CpG ODN cellular uptake and localization using a biotin detection system and light microscopy.

HY-150751B

FITC-labeled ODN TTAGGG sodium		CpG ODNs
FITC-labeled ODN TTAGGG (sodium), a inhibitory oligonucleotide (ODN), is a *TLR9, AIM2* and cGAS antagonist. FITC-labeled ODN TTAGGG (sodium) can be used to evaluate CpG ODN cellular uptake and localization by confocal laser-scanning microscopy (excitation 495 nm, emission 520 nm) or flow cytometry.

HY-177623A

CpG-ODN c41 sodium CpG-c41 sodium		CpG ODNs
CpG-ODN c41 sodium, an oligonucleotide, is an antagonist of TLR9.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

TLR antagonist

Inhibitors & Agonists

Peptides

NaturalProducts

Oligonucleotides

Natural
Products